AGTC: The New Leader in Ocular Gene Therapy with Sue Washer
Release Date: 09/21/2021
Corneal Rejuvenation with Trefoil Therapeutics
Eye Care Insider
In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :14 · Intro David Eveleth, PhD :47 · Eveleth’s background 1:05 · What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59 · The origins...
info_outline
EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System
Eye Care Insider
In this episode, I chat with Nancy Lurker, CEO and board director, about EyePoint Pharmaceuticals and their latest treatments and trials. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :13 · Intro Nancy Lurker :22 · Lurker’s background :58 · EyePoint Pharmaceuticals: the origin and transition 2:29 · Yutiq and long-acting drug delivery systems 6:07 ...
info_outline
Samsara Vision’s SING IMT: Game Changer for the Advanced AMD Patient
Eye Care Insider
In this episode, I discuss Samsara Vision’s SING IMT and its benefits of vision improvement for patients with AMD with Rebecca Kammer, OD, PhD. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :14 · Intro for Rebecca Kammer, OD, PhD :27 · Dr. Kammer’s background 1:28 · Defining late-stage AMD patients and treatments available 5:11 · The SING IMT 9:46 ...
info_outline
Dr. Mali's Top 5 Predictions in Ophthalmology for 2023
Eye Care Insider
In this episode, I share my top five predictions for 2023 in the field of ophthalmology. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :52 My review of the top five predictions in ophthalmology 1:03 Prediction #1 – Vabysmo and anti-VEGF market 1:53 Prediction #2 – FDA approval for GA treatment 4:26 Prediction #3 – for ocular protection 6:06 Prediction #4 – biosimilars and the ophthalmic therapeutic marketplace 10:08 Prediction #5 – retina analytical tools 12:27 Thanks for listening 14:30 We’d love to hear from you! Send your comments/questions...
info_outline
What Ophthalmologists Are Thankful For: Dr. Mali’s Top 5 Greatest Innovations Of The 21st Century in Ophthalmology
Eye Care Insider
In this episode, I share my thoughts about the five greatest innovations of the 21st century in the field of ophthalmology and how they have changed patient outcomes for the better. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :50 My review of the top five innovations in ophthalmology 1:02 Greatest Innovation #1 – anti-VEGF medications 2:06 Greatest Innovation #2 – intraocular lens implantation technology 3:26 Greatest Innovation #3 – electronic medical records 4:08 Greatest Innovation #4 – optical coherence tomography 5:48 Greatest Innovation #5 –...
info_outline
Dr. Mali's AAO 2022 Annual Meeting Hot Topics Post Meeting Reaction
Eye Care Insider
In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments. Brought to you by Alcon Welcome to another exciting episode of Eye Care insider :53 My review of the hot topics from the AAO 2022 annual meeting 2:20 Hot Topic #1 – wet AMD treatments 2:40 Hot Topic #2 – high-dose Eylea 6:20 Hot Topic #3 – geographic atrophy treatments 10:24 Thanks for listening 16:04 We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . Disclosures: Mali reports...
info_outline
Dr. Mali’s AAO 2022 Annual Meeting Hot Topics Preview
Eye Care Insider
In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works. Welcome to another exciting episode of Eye Care insider :52 My preview of hot topics for the upcoming AAO 2022 annual meeting 1:04 Hot Topic #1 – new treatments for dry AMD or geographic atrophy 2:43 Hot Topic #2 – wet AMD management 5:55 Hot Topic #3 – ocular gene therapy 7:56 Hot Topic #4 – biosimilars 9:17 Thanks for listening 11:22 We’d love to hear from you! Send your comments/questions to Dr. Mali at ....
info_outline
Financial Pearls for the Eye Care Professional 2022
Eye Care Insider
In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Jose Segura 1:03 For people that are listening for the first time, do you mind giving a brief of your background? 1:32 What are, in your opinion, some best practices in regard to financial planning? 2:58 Process for financial organization and seeking out advisors. 10:09 Can you talk about...
info_outline
Virtual Reality in Ophthalmology: The New Frontier with Ashlie Leal
Eye Care Insider
In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Ashlie Leal 1:00 Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33 Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56 Do you target training programs? … Is there...
info_outline
Nanodropper: The Potential Gamechanger with Allisa Song
Eye Care Insider
In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Allisa Song 1:01 I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02 What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06 Can this go on every eyedrop bottle? 6:49 Is there any...
info_outlineIn this episode, Sue Washer, BS, MBA, discusses gene therapy in ophthalmology, ATGC’s clinical trial progress, as well as current and future challenges faced by both the cell therapy industry and ophthalmology.
- Welcome to another exciting episode of Eye Care insider :13
- About Washer 1:51
- Can you discuss what is gene therapy? How does it work on a basic level? 4:53
- How do companies like AGTC make gene therapy work for diseases that may not affect as many people but still make it financially successful for investors? 7:11
- Could you talk about where you are in the X-Linked Retinitis Pigmentosa candidate trials? 11:08
- Is there an estimated timeline that you have for initial data read out? 14:56
- You have another candidate for achromatopsia … I was reading you had some new data released. Could you go into more details about that? 16:23
- What do you think is the most important topic or challenge you see facing the gene therapy industry and ophthalmology today and in the future? 20:56
- Thank you so much for your insight into this fascinating topic 23:22
- How to find out more about AGTC 23:31
- Thank you for listening 24:15
Sue Washer, BS, MBA is the president and chief executive officer of AGTC.
We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. You can contact AGTC through the company’s website at www.atgc.com.
Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Washer is the president and CEO of AGTC.